You are here

Articles

Cessation of nilotinib in patients with CML who have kept deep molecular responses for 2yrs

published: 3 October 2019

Combining Asciminib with Ponatinib Suppresses Emergence Highly Resistant BCR-ABL1 Mutants

published: 3 October 2019

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic CML

published: 3 October 2019

CML: the concepts of resistance and persistence and the relationship with BCR-ABL1

published: 3 October 2019

Cortes Highlights Second-Generation TKIs for Frontline Therapy in CML

published: 9 August 2019

Video Recordings: UK Chronic Myeloid Leukaemia Patient Day 2019

published: 15 July 2019

CML Horizons 2019 Presentations and Video streams are available now!

published: 6 July 2019

King's College London - Patient Group (July 24th)

published: 29 June 2019

De-Escalation of TKI Therapy Before Complete Treatment Discontinuation in Patients With CML

published: 26 June 2019

CML Horizons Conference Report: Lisbon Portugal May 17th - 19th 2019

published: 28 May 2019

Early results of lower dose dasatinib (50 mg daily) as frontline therapy

published: 22 May 2019

TKI Discontinuation Criteria Established in Updated NCCN Guidelines

published: 27 March 2019

Skeletal muscle toxicity associated with TKIs in CML patients

published: 18 March 2019

Falsified Iclusig / ponatinib traded globally

published: 31 January 2019

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after TFR attempts

published: 5 December 2018

UCLH study: web-based video consultations

published: 11 November 2018

£3M Award for Pioneering Scottish Trial for Leukaemia (CML)

published: 27 September 2018

BCR-ABL1 levels increase in peripheral blood but not in granulocytes after physical exercise

published: 21 August 2018

Pepsi or Coke? Influence of acid on dasatinib absorption

published: 21 August 2018

UK CML Patient Conference 2018 (22 Sept): Video Recordings Now Available

published: 14 August 2018